This review examines recent advances in neoantigen cancer vaccine development, highlighting clinical progress across cancer types while discussing ongoing challenges and opportunities to enhance vaccine design, delivery, and combination immunotherapy approaches.
Abstract
The success of immunotherapies such as immune checkpoint blockade and engineered T-cells has demonstrated the immune system’s anticancer potential. Although prophylactic vaccines against oncogenic viruses such as human papillomavirus prevent cancer by blocking infection, therapeutic vaccines targeting tumour-associated or tumour-specific antigens (TAAs/TSAs) have not reliably produced meaningful tumour regressions. Advances in DNA sequencing and computational pipelines for predicting individual, MHC-restricted neoantigens now enable personalized cancer vaccines (PCVs). By targeting neoantigens arising from somatic mutations, PCVs escape the central tolerance that limits anti-TAA vaccines. Multiple clinical trials have shown promise, but PCV design, delivery, and optimal disease settings require further refinement. This review examines recent advances in neoantigen cancer vaccine development, highlighting clinical progress across cancer types while discussing ongoing challenges and opportunities to enhance vaccine design, delivery, and combination immunotherapy approaches.
Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy, and Artificial Intelligence and Machine Learning are increasingly being incorporated into neoantigen identification pipelines to imp...
D. Mhanna, Bilal Salman, Rawad El Hakim et al.· Therapeutic Advances in Vacc...· 0 citations
By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combinati...
T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al.· International Journal of Mol...· 0 citations
Current progress in cancer vaccine research is summarized, major translational challenges are discussed, and future directions for the development of effective vaccine-based cancer therapies are considered.
BACKGROUND
With the rapid advancements in oncology, immunology, and molecular biology, immunotherapy has emerged as a cornerstone of anti-tumor treatment, complementing traditional modalities such as surgery, radiotherapy, and chemotherapy. Therapeutic cancer vaccines are a promising immunotherapy strategy that deliver...
Ju-Wei Gao, Yue Sun, Zi-Jing Han et al.· Immunological Investigations· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.